Tarsus Pharmaceuticals (TARS) closed at $68.60 on November 6, 2026, up 1.6% from the previous close, on volume of 787,430 shares (30-day average 1,006,130).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 20, 2026 | Strangle or Risk Reversal | 16-Apr-2760 P : 85 C | 322 |
| 2-2 | The next 1 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Tarsus to Participate in Upcoming Investor Conferences
Globe Newswire (Thu, 5-Nov 4:30 PM ET)
Guggenheim Keeps Their Buy Rating on Tarsus Pharmaceuticals (TARS)
TipRanks (Thu, 5-Nov 7:16 AM ET)
TipRanks (Wed, 4-Nov 4:00 PM ET)
Seeking Alpha News (Tue, 3-Nov 4:52 PM ET)
Tarsus Reports Third Quarter 2026 Financial Results
Globe Newswire (Tue, 3-Nov 4:05 PM ET)
Tarsus to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026
Globe Newswire (Thu, 29-Oct 4:30 PM ET)
Tarsus Pharmaceuticals Appoints Neera Clase as Chief Commercial Officer
Globe Newswire (Wed, 28-Oct 8:30 AM ET)
Lisata Therapeutics Appoints Jeff Farrow to Board of Directors
Globe Newswire (Wed, 14-Oct 4:05 PM ET)
Globe Newswire (Tue, 29-Sep 8:30 AM ET)
Globe Newswire (Fri, 4-Sep 8:38 AM ET)
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
Tarsus Pharmaceuticals trades on the NASDAQ stock market under the symbol TARS.
As of November 6, 2026, TARS stock price climbed to $68.60 with 787,430 million shares trading.
TARS has a beta of 0.39, meaning it tends to be less sensitive to market movements. TARS has a correlation of 0.01 to the broad based SPY ETF.
TARS has a market cap of $3.21 billion. This is considered a Mid Cap stock.
Last quarter Tarsus Pharmaceuticals reported $195 million in Revenue and -$.78 earnings per share. This beat revenue expectation by $4 million and exceeded earnings estimates by $.92.
In the last 3 years, TARS traded as high as $91.53 and as low as $15.47.
The top ETF exchange traded funds that TARS belongs to (by Net Assets): VTI, FBT, IWM, VXF, IWO.
TARS has underperformed the market in the last year with a return of +0.7%, while SPY returned +10.8%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in TARS shares. However, TARS has outperformed the market in the last 3 month and 2 week periods, returning +5.0% and +0.6%, while SPY returned -4.1% and -3.2%, respectively. This indicates TARS has been having a stronger performance recently.
TARS support price is $65.25 and resistance is $69.79 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TARS shares will trade within this expected range on the day.
